On pages 1201 and 1202 Figs. 2 and 3 were printed with the wrong legends. For the reader's convenience, both [Fig. 2](#fig1){ref-type="fig"}, [Fig. 3](#fig2){ref-type="fig"} appear here with the correct legends.Fig. 2Vero cells were infected with SARS-CoV and treated with dilutions of aurintricarboylic acid, IFN-α and IFN-β. At 24 h post-infection, supernatant samples were harvested to perform plaque assay. The virus titers of ATA treated and untreated samples were calculated and represented by plaque-forming unit (A). Cells were also pretreated with the same dilutions of ATA, IFN-α and IFN-β and then the plaque assay was performed (B). The experiments were repeated at least 3 times, with SD being approximately 10%.Fig. 3(A) Vero cells were infected with SARS-CoV and treated with serially diluted concentrations of aurintrucarboxylic acid. After 24 h, cells were harvested and subjected to 4--12% SDS--PAGE; protein samples were subsequently transferred to PVDF membrane and probed with a mouse monoclonal antibody against SARS-CoV spike protein and anti-α-actinin antibodies. A rabbit anti-mouse antibody conjugated with horseradish peroxidase was used as the secondary antibody. The blot was subsequently developed with SuperSignal West Femto Western Blot kit. (B) HEK293 cells were transfected with andenovirus X construct expressing EGFP. After 24 h, cells were harvested and subjected to 4--12% SDS--PAGE; protein samples were subsequently transferred to PVDF membrane and probed with mouse monoclonal antibody against EGFP (for HEK293 cell extracts), and anti-α-actinin antibodies. A rabbit anti-mouse antibody conjugated with horseradish peroxidase was used as the secondary antibody. The blot was subsequently developed with SuperSignal West Femto Western Blot kit (Pierce, Rockford, IL).
